Xencor Inc Revenue Growth Rates (XNCR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Xencor Inc  (NASDAQ: XNCR)
 

XNCR's Revenue Growth by Quarter and Year

Xencor Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/XNCR/growth
https://api.csimarket.com/api/v1/companies/XNCR/fundamentals
https://api.csimarket.com/api/v1/companies/XNCR/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
XNCR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 116.52
2nd Quarter June 51.22
1st Quarter March 4.52
FY 172.26

XNCRs Annual Revenue
Xencor Inc's Revenue in the fiscal year 2025 $ 125.58 millions
Xencor Inc's Revenue in the fiscal year 2024 $ 110.49 millions
Xencor Inc's Revenue in the fiscal year 2023 $ 174.62 millions
Xencor Inc's Revenue in the fiscal year 2022 $ 164.58 millions
Xencor Inc's Revenue in the fiscal year 2021 $ 275.11 millions




XNCR Revenue third quarter 2026 Y/Y Growth Comment
Xencor Inc achieved in the third quarter 2026, above Company average Revenue surge of 454.86% year on year, to $ 116.52 millions.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 71 other companies have achieved higher Revenue growth. While Xencor Inc' s Revenue doubling of 454.86% ranks overall at the positon no. 1078 in the third quarter 2026.


XNCR Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 454.86 %
2nd Quarter June 17.45 %
1st Quarter March -86.19 %
FY   -

Financial Statements
Xencor Inc's third quarter 2026 Revenue $ 116.52 millions XNCR's Income Statement
Xencor Inc's third quarter 2025 Revenue $ 21.00 millions Quarterly XNCR's Income Statement


XNCR Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 127.49 %
2nd Quarter June 1033.19 %
1st Quarter March -83.99 %
FY (Year on Year)   -


Back to XNCR Growth rate Comparisons >> Back to XNCR Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #72
Healthcare Sector #204
Overall #1078

Revenue Y/Y Growth Statistics
High Average Low
992.56 % 80.39 % -69.98 %
(Jun 30 2016)   (Mar 31 2023)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #72
Healthcare Sector #204
Overall #1078
Revenue Y/Y Growth Statistics
High Average Low
992.56 % 80.39 % -69.98 %
(Jun 30 2016)   (Mar 31 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Xencor Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1034.21 % 112.09 % -100 %
(Jun 30 2026)  


XNCR's III. Quarter Q/Q Revenue Comment
Xencor Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 127.49%, to $ 116.52 millions, from $51.22 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Revenue quarter on quarter growth. While Xencor Inc's Revenue growth quarter on quarter, overall rank is 30.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #9
Healthcare Sector #12
Overall #30
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #9
Healthcare Sector #12
Overall #30
Revenue Q/Q Growth Statistics
High Average Low
1034.21 % 112.09 % -100 %
(Jun 30 2026)  


XNCR's III. Quarter Q/Q Revenue Comment
Xencor Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 127.49%, to $ 116.52 millions, from $51.22 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Revenue quarter on quarter growth. While Xencor Inc's Revenue growth quarter on quarter, overall rank is 30.


Xencor Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 104.97
Y / Y Revenue Growth (TTM) -28.56 %
Year on Year Revenue Growth Overall Ranking # 2834
Seqeuential Revenue Change (TTM) 7.82 %
Seq. Revenue Growth (TTM) Overall Ranking # 1089


Cumulative Revenue growth Comment
Xencor Inc's cumulative 12 months Revenue continue to drop, but on the faster rate at -28.56% year on year, at Jun 30 2026 compare to the -23.48% decrease at Mar 31 2026. If the Xencor Inc's fiscal year would end at Jun 30 2026, annual Revenue would be $105 millions.

In the Healthcare sector 399 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2834, from total ranking in previous quarter at 2920.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 72
Healthcare Sector # 400
Overall # 2834

Revenue TTM Y/Y Growth Statistics
High Average Low
992.56 %
 80.39 %
-69.98 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 72
Sector # 205
S&P 500 # 1089
Cumulative Revenue growth Comment
Xencor Inc's cumulative 12 months Revenue continue to drop, but on the faster rate at -28.56% year on year, at Jun 30 2026 compare to the -23.48% decrease at Mar 31 2026. If the Xencor Inc's fiscal year would end at Jun 30 2026, annual Revenue would be $105 millions.

In the Healthcare sector 399 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2834, from total ranking in previous quarter at 2920.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 72
Healthcare Sector # 400
Overall # 2834

Revenue TTM Y/Y Growth Statistics
High Average Low
992.56 %
80.39 %
-69.98 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 72
Sector # 205
S&P 500 # 1089




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
XNCR's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Pmgc Holdings Inc 784.90%$ 784.904 millions
Abeona Therapeutics Inc 706.88%$ 706.878 millions
Brightspring Health Services Inc 588.43%$ 588.428 millions
Bio Green Med Solution Inc 460.49%$ 460.494 millions
Xencor Inc454.88%$ 454.884 millions
Tonix Pharmaceuticals Holding Corp 423.83%$ 423.830 millions
Nakamoto Inc 396.90%$ 396.897 millions
EBR Systems, Inc.385.65%$ 385.647 millions
Solana Company382.07%$ 382.066 millions
Pulse Biosciences Inc 359.30%$ 359.302 millions
Ensysce Biosciences Inc 342.43%$ 342.428 millions
Nexalin Technology Inc 331.43%$ 331.434 millions
Agios Pharmaceuticals Inc 330.01%$ 330.008 millions
Insmed Inc330.00%$ 330.000 millions
Monte Rosa Therapeutics Inc 325.80%$ 325.799 millions
Liquidia Corporation314.60%$ 314.596 millions
Stablecoin Development Corporation310.75%$ 310.749 millions
Renovorx Inc 300.75%$ 300.752 millions
Aligos Therapeutics Inc 281.92%$ 281.916 millions
Clene Inc 273.33%$ 273.333 millions
Recursion Pharmaceuticals Inc 258.49%$ 258.493 millions
Nuvation Bio Inc 251.98%$ 251.977 millions
Seastar Medical Holding Corp246.99%$ 246.995 millions
Prime Medicine Inc 243.92%$ 243.918 millions


About Xencor Inc Revenue Growth Rates (XNCR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Xencor Inc (CIK 1326732).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001326732-26-000063
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Xencor Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.